Gts Securities LLC Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$233.81 - $287.01 $6.24 Million - $7.66 Million	-26,700 Reduced 49.54%	27,200 $7.48 Million
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $945,846 - $1.63 Million	6,600 Added 13.95%	53,900 $13.1 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $820,456 - $1.11 Million	5,600 Added 13.43%	47,300 $7.07 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $45,423 - $58,971	300 Added 0.72%	41,700 $7.98 Million
Q3 2023 Nov 15, 2023	BUY	$170.77 - $211.65 $7.07 Million - $8.76 Million	41,400 New	41,400 $7.33 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.